Apoquel 1 Chewable Tablet 5.4mg (1 tablet)

Apoquel Chewable 1 Tablet 5.4mg contains oclacitinib, an active substance specifically formulated to address the underlying causes of itching and inflammation in dogs. It works by modulating the immune system to help reduce the itch and inflammation commonly seen in allergic skin diseases.

As a Prescription Only Medicine (POM-V), Apoquel Chewable 1 Tablet 5.4mg must be prescribed by your veterinarian. Weldricks Pharmacy makes it easy and convenient to obtain your pet's prescription medication, ensuring your beloved companion receives the care they need quickly and reliably. Our discreet packaging and free UK delivery options over £40 mean you can get your pet's treatment delivered directly to your door with ease.

Understanding Allergic Dermatitis & Atopic Dermatitis in Dogs

Allergic Dermatitis: This is a common skin condition in dogs, often triggered by environmental allergens (like pollen, dust mites) or food. It results in intense itching, redness, and inflammation, which can significantly impact your dog's quality of life.

Atopic Dermatitis: A chronic allergic skin condition, atopic dermatitis causes persistent itching and inflammation, often leading to secondary infections. Apoquel Chewable 1 Tablet 5.4mg helps manage these uncomfortable symptoms, providing much-needed relief for your pet.

Administering Apoquel Chewable 1 Tablet 5.4mg is straightforward, as the tablets are chewable and palatable, making them readily accepted by most dogs. Always follow your veterinarian's specific dosage instructions to ensure the best outcome for your pet.

Apoquel Chewable 1 Tablet 5.4mg is for oral use in dogs. Always administer exactly as directed by your veterinary surgeon.

• The recommended initial dose is 0.4 to 0.6 mg oclacitinib per kg bodyweight, administered orally, twice daily for up to 14 days.
• For maintenance therapy (after the initial 14 days), the same dose (0.4 to 0.6 mg oclacitinib per kg bodyweight) should be administered only once a day.
• The requirement for long-term maintenance therapy should be based on an individual benefit-risk assessment by your veterinarian.
• Apoquel Chewable 1 Tablet 5.4mg can be administered with or without food.
• Dogs should be carefully observed following administration to ensure that each tablet is swallowed.

When Not to Use Apoquel Chewable 1 Tablet 5.4mg

Do not use this veterinary medicinal product in the following cases:

• In cases of hypersensitivity to the active substance (oclacitinib) or any of the excipients.
• In dogs less than 12 months of age or weighing less than 3 kg bodyweight.
• In dogs with evidence of immune suppression, such as hyperadrenocorticism.
• In dogs with evidence of progressive malignant neoplasia.
• The safety of the veterinary medicinal product has not been established during pregnancy and lactation, or in breeding male dogs. Therefore, its use is not recommended during pregnancy, lactation, or in dogs intended for breeding.

Important Precautions

• Oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions. Dogs receiving Apoquel Chewable 1 Tablet 5.4mg should therefore be monitored for the development of infections and neoplasia.
• When treating pruritus associated with allergic dermatitis, underlying causes (e.g., flea allergic dermatitis, contact dermatitis, food hypersensitivity) should be investigated and treated.
• Complicating factors such as bacterial, fungal, or parasitic infections/infestations (e.g., flea and mange) should also be investigated and treated.
• For dogs on long-term treatment, periodic monitoring with complete blood counts and serum biochemistry is recommended due to potential effects on clinicopathological parameters.

Potential Side Effects (Adverse Events)

Like all medicines, Apoquel Chewable 1 Tablet 5.4mg can cause side effects, although not all dogs will experience them. If you notice any side effects, even those not listed here, or if the medicine has not worked, please contact your veterinarian.

• Very common (more than 1 in 10 animals treated): pyoderma (skin infection), skin lump, papilloma.
• Common (1 to 10 in 100 animals treated): lethargy (tiredness), lipoma (fatty tumour), polydipsia (increased thirst), increased appetite, nausea, vomiting, diarrhoea, anorexia (loss of appetite), histiocytoma (benign skin tumour), fungal skin infection, pododermatitis (inflammation of paw skin), otitis (ear infection), lymphadenopathy (enlarged lymph nodes), cystitis (bladder inflammation), aggression.
• Very rare (less than 1 in 10,000 animals treated, including isolated reports): anaemia, lymphoma.

Treatment-related clinical pathology changes included an increase in mean serum cholesterol and a decrease in mean leukocyte count; however, all mean values remained within laboratory reference range. The decrease in mean leukocyte count was not progressive and affected all white blood cell counts except lymphocyte counts, and these changes did not appear clinically significant.

Precautions for the Person Administering the Product

• Wash hands immediately after administration.
• In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
• Ingestion of this product may be harmful for children. To avoid accidental ingestion, administer the tablet(s) to the dog immediately after removal from the blister packaging. Store tablets in a safe place out of reach of animals.

Each Apoquel Chewable 1 Tablet 5.4mg contains:

Active substance:

• 5.4 mg oclacitinib (as oclacitinib maleate)

Excipients (other constituents):

• Pork liver powder
• Crospovidone (type A)
• Sodium starch glycolate (type A)
• Glycerol monostearate 40-55 (type II)
• Macrogol 3350
• Glycerol
• Sodium chloride
• Xanthan gum
• Brewer's yeast dried
• Silica colloidal anhydrous
• Magnesium stearate